Nutritional status monitoring for adults with gastroenteropancreatic neuroendocrine tumors
Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital
This project will see if nutrition problems are common and linked to outcomes in adults aged 18–70 being followed for gastroenteropancreatic neuroendocrine tumors at Strasbourg University Hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Drugs / interventions | sunitinib, chemotherapy |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT07302100 on ClinicalTrials.gov |
What this trial studies
This observational study will collect historical and current nutritional data from adults aged 18–70 who have been followed for gastroenteropancreatic neuroendocrine tumors at CHU de Strasbourg between 1 January 2000 and 30 November 2024. Investigators will record measures such as weight, body mass index, laboratory nutritional markers, and any documented nutritional interventions, and will relate these to tumor features and clinical outcomes. No experimental treatments are given; the protocol is descriptive and aims to characterize the prevalence and pattern of malnutrition in this patient group. Results are intended to inform nutritional screening and management pathways for patients with typically slow‑growing gastroenteropancreatic NETs.
Who should consider this trial
Good fit: Adults aged 18 to 70 diagnosed with a gastric, pancreatic, or intestinal neuroendocrine tumor between 1 January 2000 and 30 November 2024 who are followed at the CHU de Strasbourg endocrine/nutrition service.
Not a fit: Patients outside the 18–70 age range, those not followed at CHU de Strasbourg, or those whose tumors were reclassified as non‑neuroendocrine by pathology are unlikely to receive direct benefit from participation.
Why it matters
Potential benefit: If successful, the study could help clinicians identify patients at risk of malnutrition earlier and guide nutritional care that may improve quality of life and clinical outcomes.
How similar studies have performed: Prior cancer research has shown that malnutrition predicts poorer outcomes and that nutritional interventions can improve results, but targeted evidence specifically for gastroenteropancreatic neuroendocrine tumors remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 to 70 years * Patients being monitored for a digestive neuroendocrine tumor (gastric, pancreatic, intestinal), diagnosed between January 1, 2000, and November 30, 2024 Exclusion Criteria: \- Tumor reclassified as non-neuroendocrine by histopathology
Where this trial is running
Strasbourg
- Service d'Endocrinologie, Diabétologie, Nutrition - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Philippe BALTZINGER, MD
- Email: philippe.baltzinger@chru-strasbourg.fr
- Phone: 33 3 88 12 75 82
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.